TREVI THERAPEUTICS INC

Trevi Therapeutics (TRVI) trades under its 200‑day MA at $12.61, with a strong $250M cash buffer and upcoming Phase‑2a data for IPF in Q3 2027. Watch the next milestone for a potential upside.

Trevi Therapeutics jumps 7.8% to $12.83, but analysts warn the surge is speculative, below the 200‑day SMA and a modest 1.7 bn cap.

Trevi Therapeutics (TRVI) gains 0.17% as investors monitor its 200‑day MA, while the company focuses on nalbuphine‑ER for cough and levodopa‑induced dyskinesia.